High-Dose Influenza Vaccine Offers Superior Protection Against Hospitalization in Older Adults Regardless of Diabetes Status

Introduction: The Dual Threat of Influenza and Diabetes in the Aging Population

Influenza remains a formidable public health challenge, particularly for the geriatric population. For individuals aged 65 years and older, the intersection of immunosenescence—the gradual decline of the immune system with age—and chronic comorbidities creates a landscape of high vulnerability. Among these comorbidities, diabetes mellitus stands out as a significant risk factor for severe influenza-related outcomes. Patients with diabetes are not only at a higher risk of contracting the virus but are also more likely to experience severe complications, including pneumonia, cardiovascular events, and prolonged hospitalizations.

While the high-dose inactivated influenza vaccine (HD-IIV) has been shown to provide superior protection compared to the standard-dose inactivated influenza vaccine (SD-IIV) in the general elderly population, its specific efficacy within the diabetic subgroup has remained a subject of clinical inquiry. The DANFLU-2 trial’s secondary analysis provides much-needed clarity on whether the increased antigen content of HD-IIV translates into tangible clinical benefits for this high-risk demographic.